Focusing on critical regulators, such as FSP1, MCU, and SMAD4, along with leveraging the vulnerabilities linked to ferroptosis, presents a promising avenue for enhancing treatment outcomes in patients with pancreatic cancer. The gene discussed is SMAD4; the disease is familial pancreatic carcinoma.